WOBURN, Mass.--(BUSINESS WIRE)--Aphios Corporation today announced that it has been granted United States Patent No. 8,703,727 entitled “Nanotechnology Formulation of Poorly Soluble Compounds,” for difficult to formulate and deliver drugs.
Poorly soluble drug candidates are difficult to administer even as intravenous drugs. Low concentrations may limit therapeutic response and require long infusion periods which are poorly tolerated and raise the risk of infection. Administered orally, the drugs are often poorly absorbed. Lack of sufficient oral bioavailability hinders development of potential drug candidates to their full potential. By enhancing the solubility and oral bioavailability of such compounds, therapeutically beneficial products can be developed, especially where long-term exposure is needed for maximum therapeutic effect. These techniques can be applied to a number of existing drugs as well as to several potential drug candidates being developed by the National Cancer Institute and in the cancer pipeline of pharmaceutical and biotechnology companies.
Help employers find you! Check out all the jobs and post your resume.
